NIH launches phase 3 investigational trials for pair of monoclonal antibody therapies for COVID-19

Dec 18, 2020 - 02:36 PM
NIH-cancer-deaths

The National Institutes of Health yesterday announced enrollment in phase 3 of the clinical trial of two disparate therapies. This trial is specifically looking at the safety and effectiveness of the therapeutics in people hospitalized with moderate COVID-19 symptoms.

The two approaches being tested are the use of VIR-7831, a monoclonal antibody developed through a partnership between GlaxoSmithKline and Vir Biotechnology, Inc., and a combination of neutralizing monoclonal antibodies, BRII-196 and BRII-198, that are manufactured by Brii Biosciences.

Initially, approximately 450 people will be enrolled, with a third of participants receiving a placebo, a third receiving VIR-7831 and a third getting the combination of Brii therapeutics. It the trials appear successful, an additional 700 people hospitalized with COVID-19 will be enrolled. 

Related News Articles

Headline
CDC encourages older adults to get additional COVID-19 vaccine dose 
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
NASEM releases evidence review on COVID-19 vaccine safety
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
CDC recommends additional dose of updated COVID-19 vaccine for older adults
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
CDC study finds low rates of COVID-19, flu and RSV vaccinations in adults 
A CDC study  released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Headline
CDC: COVID-19, flu vaccination rates for health care workers low last season
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23…
Headline
FDA clarifies Moderna COVID-19 vaccine dosage for children under 12
Children under age 12 should receive a 0.25 milliliter dose of the 2023-24 Moderna COVID-19 vaccine, not the full vial for that age group, the Food and Drug…